APA (7th ed.) Citation

R, B., P, T., N, T., C, D., DA, Y., SJ, I., . . . SM, T. (2022). Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): A randomized controlled trial. NPJ breast cancer, 8(1), 18. https://doi.org/10.1038/s41523-022-00385-2

Chicago Style (17th ed.) Citation

R, Barroso-Sousa, et al. "Cardiac Outcomes of Subjects on Adjuvant Trastuzumab Emtansine Vs Paclitaxel in Combination with Trastuzumab for Stage I HER2-positive Breast Cancer (ATEMPT) Study (TBCRC033): A Randomized Controlled Trial." NPJ Breast Cancer 8, no. 1 (2022): 18. https://doi.org/10.1038/s41523-022-00385-2.

MLA (9th ed.) Citation

R, Barroso-Sousa, et al. "Cardiac Outcomes of Subjects on Adjuvant Trastuzumab Emtansine Vs Paclitaxel in Combination with Trastuzumab for Stage I HER2-positive Breast Cancer (ATEMPT) Study (TBCRC033): A Randomized Controlled Trial." NPJ Breast Cancer, vol. 8, no. 1, 2022, p. 18, https://doi.org/10.1038/s41523-022-00385-2.